Research Reports

  • 14 September 2017

    Emerging rivals in CAR-T cell therapies

    The recent acquisition deal by Gilead for Kite Pharma has meant a huge opportunity for the biopharmaceutical to provide an opportunity for novel cancer immunotherapies.

Close
Close
Close

Go Top